AusBiotech announces incoming CEO
Posted: 23 April 2024 Australia’s industry body for biotechnology, AusBiotech, has announced ex-Sanofi leader Rebekah Cassidy as its incoming Chief Executive Officer. Rebekah is an experienced leader with extensive strategy, policy, and media proficiency, coupled with deep health…
From Mines to Medicines – Australia Poised to Lead a Life-saving Revolution in Radiopharmaceuticals
Posted: 19 April 2024 A new discussion paper from MTPConnect reveals how Australia is ready to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies drive significant investment and rapid expansion. Radiopharmaceuticals…
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76
Posted: 19 April 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with the Centre for Human…
New arrivals boost Hudson’s inflammation research leadership
Posted: 19 April 2024 Hudson Institute’s reputation as a leader in inflammation research has been boosted by the appointment of two specialists in the field. Director and CEO Professor Elizabeth Hartland today announced that Professor Carl Walkley and Dr Sophia…
Increased monitoring capacity of deadly prion diseases
Posted: 19 April 2024 A state-of-the-art service based at The Florey is increasing its capacity to protect the public from the fatal brain condition Creutzfeldt-Jakob disease (CJD). The rare neurodegenerative illness, caused by misfolded proteins called prions in…
Melbourne home to one-of-a-kind electron microscope
Posted: 19 April 2024 A suite of three electron microscopes, including one of the highest resolution microscopes in the world, now calls Monash home, helping scientists push the frontiers in materials science to solve complex worldwide challenges. The…
IDT Secures contract with Sanofi Australia
Posted: 19 April 2024 IDT Australia Limited (ASX: IDT) (IDT Australia) is pleased to announce that it has entered into a Master Service Agreement with Sanofi, an innovative global healthcare company, to support the preclinical formulation development and…
Receive a discount on research and clinical trial training programs
Posted: 17 April 2024 In the lead up to the EOFY, BioMelbourne Network partner PRAXIS Australia are offering you and your team their most generous offer yet on their expert training solutions. If you enrol now, you can receive 24%…
First Patient Enrolled Major e-health Respiratory Management Clinical Study
Posted: 16 April 2024 Leading digital health company Adherium Limited (ASX:ADR) is pleased to announce the first patient has been enrolled in a newly cemented research partnership between US Intermountain Health and CareCentra using Hailie® sensors to monitor…
Adherium Unveils New FDA-Cleared Smartinhaler® Compatible with Airsupra® and Breztri® Inhalation Devices
Posted: 16 April 2024 Adherium Limited ( “Adherium” or “the Company”; ASX:ADR), a global leader in digital health technologies addressing chronic respiratory diseases, is pleased to announce that its innovative Hailie® Smartinhaler® has received clearance from the U.S.…
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
Posted: 16 April 2024 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET). The granted Fast Track designation is for…
Seaport Therapeutics receives US$100 million in funding to maximise Monash invention
Posted: 16 April 2024 Seaport Therapeutics, a clinical-stage biopharmaceutical company based around a unique drug delivery platform originally developed by Monash University researchers, today announced the closing of a $100 million oversubscribed Series A financing round. The round…
